GlassScriptPhysician profile
Douglas B Knox
NPI 1043212293
$5,888.35
in general payments reported to CMS, 2019-2025
36 companies · $511 in 2025
The $511 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $294 · 2020: $742 · 2021: $821 · 2022: $1,528 · 2023: $975 · 2024: $1,018 · 2025: $511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,478 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,478.37 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,227.24 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $666.87 | 2021-2025 | Airsupra, Farxiga, Fasenra |
| Teva Pharmaceuticals USA, INC. | $550.24 | 2021-2025 | Austedo Xr, Ajovy, Austedo |
| Daiichi Sankyo INC. | $516.43 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $482.44 | 2020-2025 | Acthar |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $373.21 | 2021-2025 | Xifaxan |
| Ani Pharmaceuticals, INC. | $278.05 | 2022-2025 | Purified Cortrophin Gel |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $207.77 | 2025 | Caplyta |
| Lilly USA, LLC | $197.47 | 2021-2025 | Zepbound, Mounjaro |
| Novo Nordisk INC | $179.57 | 2023-2024 | Wegovy, Rybelsus |
| Astellas Pharma US INC | $162.76 | 2023-2025 | Veozah, Myrbetriq |
| Eisai INC. | $139.05 | 2020 | |
| Supernus Pharmaceuticals, INC. | $123.29 | 2022-2023 | Qelbree |
| Merck Sharp & Dohme LLC | $98.31 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $70.65 | 2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $55.92 | 2023-2025 | Quviviq, Quviviq |
| Mallinckrodt Enterprises LLC | $53.93 | 2019 | |
| Pfizer INC. | $47.60 | 2019-2024 | |
| Angiodynamics, INC. | $47.34 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.40 | 2021 | |
| Neurocrine Biosciences, INC. | $41.47 | 2024 | Ingrezza |
| Allergan, INC. | $38.85 | 2020 | |
| Sunovion Pharmaceuticals INC. | $37.21 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.46 | 2022 | |
| Vistapharm, INC. | $27.72 | 2021 | |
| Currax Pharmaceuticals LLC | $25.00 | 2023 | Nexletol |
| Tersera Therapeutics LLC | $23.56 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $21.05 | 2022 | |
| Genentech USA, INC. | $17.89 | 2021 | |
| Global Blood Therapeutics, INC. | $17.37 | 2020 | |
| Alnylam Pharmaceuticals INC. | $15.60 | 2024 | Givlaari |
| Collegium Pharmaceutical, INC. | $15.10 | 2020 | |
| Nabriva Therapeutics, Plc | $14.58 | 2020 | |
| Exact Sciences Corporation | $14.40 | 2025 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $13.36 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $13.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Knox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.